GET DAILY SIGNALSMerck (MRK) Q2 2026 Earnings: Revenue Beat Highlights Pipeline Progress Amid Acquisition Costs
Key Takeaways
- Revenue exceeded expectations: Merck posted second-quarter 2026 sales of $16.6 billion, up 5% year over year and ahead of the $16.41 billion consensus estimate.
- Non-GAAP EPS beat convincingly: The company reported an adjusted loss of $0.13 per share, significantly better than the $0.27 loss Wall Street had forecast.
- Terns acquisition drove the bottom-line loss: Both GAAP and non-GAAP results included a $2.31 per share charge tied to the $6.8 billion acquisition of Terns Pharmaceuticals.
- New product launches gained momentum: Recently launched drugs generated $1.5 billion in quarterly revenue, more than double the $0.6 billion from the same period last year.
- Full-year revenue guidance was raised: Merck lifted and narrowed its 2026 sales outlook to $66.3 billion–$67.3 billion, while lowering EPS guidance to reflect acquisition-related costs.
Putting Merck’s Results in Context
Merck’s second-quarter 2026 results, released on August 4, came at an important time for the pharmaceutical company. With its flagship cancer immunotherapy KEYTRUDA facing eventual patent expiration later this decade, Merck has been pursuing a strategy to build a more diversified set of growth drivers. This quarter provided a useful snapshot of how that effort is translating into actual sales. The numbers also reflected the impact of the company’s recent deal-making, particularly the $6.8 billion acquisition of Terns Pharmaceuticals, so investors could assess whether near-term costs are being offset by operational strength and pipeline advancement. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Numbers
Merck reported worldwide sales of $16.6 billion for the second quarter of 2026, a 5% increase from $15.8 billion in the prior-year period, or 4% excluding foreign exchange effects. The top line came in above the analyst consensus of $16.41 billion.
On the bottom line, Merck recorded a non-GAAP loss of $0.13 per share. Although a loss, this result was notably better than the consensus estimate of a $0.27 loss per share. The GAAP loss was $0.54 per share, compared with a profit of $1.76 per share in the second quarter of 2025. Both GAAP and non-GAAP figures included a $2.31 per share charge related to the Terns Pharmaceuticals acquisition.
The KEYTRUDA family, including the subcutaneous formulation KEYTRUDA QLEX, generated $8.4 billion in sales, up 4% on a constant-currency basis. WINREVAIR, the treatment for pulmonary arterial hypertension, saw sales rise 75% to $588 million. WELIREG climbed 67% to $271 million. GARDASIL vaccine sales reached $1.17 billion, up 4%. Animal Health contributed $1.78 billion, an 8% increase.
Revenue from recently launched products, including WINREVAIR, KEYTRUDA QLEX, CAPVAXIVE, OHTUVAYRE, ENFLONSIA, and others, totaled $1.5 billion, more than doubling from $0.6 billion a year earlier. Non-GAAP gross margin was 81.1%, down 1.1 percentage points, mainly due to higher inventory reserves.
Market Reaction and Investor Sentiment
Merck shares rose approximately 1.4% in pre-market trading following the earnings release on August 4, showing investor approval of the revenue beat and the performance of newer products. The stock, which closed the prior session at $127.77, traded near the upper end of its 52-week range of $77.58 to $135.05, reflecting broader market confidence in the diversification strategy.
The post-earnings move was relatively measured. The reduction in full-year EPS guidance—from $5.04–$5.16 to $2.66–$2.76—was anticipated and primarily reflects the Terns acquisition charge rather than any operational shortfall. Investors appeared to focus on the underlying sales trajectory, pipeline progress, and the raised revenue forecast.
Forward Outlook and Key Factors to Monitor
Looking ahead, Merck’s story will center on sustaining growth beyond KEYTRUDA. The company now guides for full-year 2026 revenue of $66.3 billion to $67.3 billion, implying 2% to 4% growth, and non-GAAP EPS of $2.66 to $2.76, a range that includes roughly $2.43 per share in total charges tied to the Terns deal.
Several potential catalysts are worth watching. The July FDA approval of LIPFENDRA (enlicitide), the first once-daily oral PCSK9 inhibitor for adults with hypercholesterolemia, opens a sizable cardiometabolic market. The Phase 3 readout for sac-TMT in advanced endometrial cancer met both overall survival and progression-free survival endpoints, marking the first positive pivotal data from the broad sac-TMT program that includes 17 ongoing Phase 3 trials.
In HIV, positive Phase 3 results were presented for the once-weekly oral regimen combining islatravir and lenacapavir (ISL/LEN), developed with Gilead. On the immunology side, tulisokibart met primary and key secondary endpoints in a Phase 3 ulcerative colitis induction study, though a separate trial in systemic sclerosis-associated interstitial lung disease was discontinued after missing its primary endpoint.
Operating expenses are now expected to reach $42.0 billion to $42.7 billion for the full year. Gross margin is projected around 81%. Investors should watch the pace of new product adoption, particularly LIPFENDRA’s early trajectory, along with further sac-TMT data and the competitive environment in oncology and vaccines.
Enhancing My Research with Tickeron Tools
In my regular analysis, I sometimes use Tickeron’s AI Screener to quickly filter for stocks with comparable earnings momentum or technical patterns. It helps surface relevant ideas more efficiently than manual screening alone, which complements the earnings review process without replacing traditional due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
MRK in -2.41% downward trend, declining for three consecutive days on November 06, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MRK declined for three days, in 140 of 273 cases, the price declined further within the following month. The odds of a continued downward trend are 51%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for MRK crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 44%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 33 of 52 cases where MRK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 63%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MRK as a result. In 55 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for MRK just turned positive on October 30, 2026. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in 27 of 50 cases over the following month. The odds of a continued upward trend are 54%.
MRK moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +6.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 191 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 177 of 265 cases where MRK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 12 (best 1 - 100 worst), indicating outstanding price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 29 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.633) is normal, around the industry mean (-1.421). MRK's P/E Ratio (116.452) is considerably higher than the industry average of (21.700). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of human and animal health products
Industry PharmaceuticalsMajor
Advertisement